Fludarabine + Melphalan + Methotrexate + Tacrolimus regimen

This is a combination therapy used in allogeneic hematopoietic stem cell transplantation (HSCT). The regimen consists of: 1. **Fludarabine and Melphalan**: These form the backbone of a reduced-intensity conditioning (RIC) regimen that helps prepare the patient's body for transplantation by suppressing the immune system and creating space for donor cells[2][4]. 2. **Tacrolimus and Methotrexate**: These medications are used together for graft-versus-host disease (GVHD) prophylaxis after transplantation[1][5]. This combination has demonstrated efficacy in patients with acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and other advanced hematological malignancies[2][3]. Studies have shown that this regimen is associated with: - Low treatment-related mortality (TRM)[1][3] - Moderate control of GVHD[1] - Good disease control without excessive non-relapse mortality (NRM)[3] - Favorable long-term overall survival (OS)[3] The regimen is particularly valuable for reduced-intensity conditioning, which allows transplantation in patients who might not tolerate more intensive myeloablative regimens due to age, comorbidities, or prior treatments[2][4].